| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 7.787 | 21.145 | 70.472 | 61.438 | 119.509 |
| Total Income - EUR | - | - | - | - | - | 7.787 | 21.395 | 70.647 | 61.460 | 119.693 |
| Total Expenses - EUR | - | - | - | - | - | 1.987 | 11.830 | 32.996 | 37.676 | 47.557 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 5.801 | 9.564 | 37.650 | 23.784 | 72.137 |
| Net Profit/Loss - EUR | - | - | - | - | - | 5.580 | 8.922 | 35.873 | 23.170 | 68.546 |
| Employees | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Oncostudmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 3.057 | 35.543 | 31.366 | 25.999 |
| Current Assets | - | - | - | - | - | 5.839 | 5.848 | 44.363 | 26.082 | 46.889 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 120 | 0 |
| Receivables | - | - | - | - | - | 1.729 | 1.029 | 37.475 | 21.220 | 35.137 |
| Cash | - | - | - | - | - | 0 | 4.819 | 6.888 | 4.741 | 11.752 |
| Shareholders Funds | - | - | - | - | - | 5.621 | 8.970 | 35.922 | 23.219 | 68.594 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 217 | 194 | 44.675 | 34.998 | 5.493 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncostudmed S.r.l.